ATE455103T1 - Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate - Google Patents

Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate

Info

Publication number
ATE455103T1
ATE455103T1 AT06785361T AT06785361T ATE455103T1 AT E455103 T1 ATE455103 T1 AT E455103T1 AT 06785361 T AT06785361 T AT 06785361T AT 06785361 T AT06785361 T AT 06785361T AT E455103 T1 ATE455103 T1 AT E455103T1
Authority
AT
Austria
Prior art keywords
sup
phenylglycinamide
pyridylglycinamide
derivatives used
anticoagulation agents
Prior art date
Application number
AT06785361T
Other languages
English (en)
Inventor
Xiaojun Zhang
Alexandra A Nirschl
Yan Zou
Eldon Scott Priestley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE455103T1 publication Critical patent/ATE455103T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/34Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06785361T 2005-06-24 2006-06-22 Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate ATE455103T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69407605P 2005-06-24 2005-06-24
US69407405P 2005-06-24 2005-06-24
PCT/US2006/024345 WO2007002313A2 (en) 2005-06-24 2006-06-22 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

Publications (1)

Publication Number Publication Date
ATE455103T1 true ATE455103T1 (de) 2010-01-15

Family

ID=37467511

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06785361T ATE455103T1 (de) 2005-06-24 2006-06-22 Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate

Country Status (6)

Country Link
US (1) US7456195B2 (de)
EP (1) EP1910298B1 (de)
AT (1) ATE455103T1 (de)
DE (1) DE602006011752D1 (de)
ES (1) ES2337831T3 (de)
WO (1) WO2007002313A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828152B1 (de) * 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Heterocyclische verbindungen als inhibitoren von faktor viia
DE602006016566D1 (de) 2005-01-10 2010-10-14 Bristol Myers Squibb Co Als antikoagulanzien verwendbare phenylglycinamid-derivate
PE20071132A1 (es) * 2005-12-23 2007-12-14 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
CN101500993A (zh) 2006-06-08 2009-08-05 百时美施贵宝公司 作为凝血因子Ⅶa抑制剂用作抗凝血药的2-氨基羰基苯基氨基-2-苯基乙酰胺
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
EP2099783A1 (de) * 2006-12-20 2009-09-16 Brystol-Myers Squibb Company Als antikoagulanzien bicyclische lactam-faktor-viia-hemmer
EP2191887A1 (de) 2008-11-26 2010-06-02 Polymers CRC Limited Anklickbare Dünnschichtverbundpolyamidmembrane
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
JPWO2011043359A1 (ja) 2009-10-06 2013-03-04 協和発酵キリン株式会社 芳香族複素環化合物を含有する医薬
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
US9174974B2 (en) 2012-06-08 2015-11-03 Bristol-Myers Squibb Company Macrocyclic factor VIIa inhibitors
CA2894399A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
PL3292116T3 (pl) 2015-02-02 2022-02-21 Valo Health, Inc. 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac
UY36548A (es) 2015-02-05 2016-06-01 Bayer Cropscience Ag Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas
TWI713530B (zh) 2015-06-05 2020-12-21 美商艾佛艾姆希公司 作為除草劑之嘧啶氧基苯衍生物
JP6845165B2 (ja) * 2015-06-30 2021-03-17 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Egfr阻害剤およびその使用方法
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
EP3319968A1 (de) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclische n-aminophenyl-amide als inhibitoren der histondeacetylase
CN105481733A (zh) * 2015-12-30 2016-04-13 苏州诚和医药化学有限公司 一种一步法合成2-甲氧基-5-氨磺酰基苯甲酸甲酯的方法
HUE057849T2 (hu) 2017-01-11 2022-06-28 Alkermes Inc Hiszton deacetiláz biciklusos gátlói
LT3664802T (lt) 2017-08-07 2022-06-27 Alkermes, Inc. Bicikliniai histonų deacetilazės inhibitoriai
CN111606827B (zh) * 2020-06-23 2022-10-25 内蒙古京东药业有限公司 一种制备依度沙班手性胺中间体的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2667864B2 (fr) 1990-03-07 1994-08-05 Rhone Poulenc Sante Derives de n-phenyl glycinamides, leur preparation et les medicaments les contenant.
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
DK0921116T3 (da) 1997-12-04 2003-10-06 Hoffmann La Roche N-(4-carbamimido-phenyl)-glycinamidderivater
KR20010082515A (ko) 1998-02-17 2001-08-30 우에노 도시오 아미디노 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
KR100473966B1 (ko) 1998-12-14 2005-03-08 에프. 호프만-라 로슈 아게 페닐글리신 유도체
EP1144373B1 (de) 1999-01-13 2005-10-19 Genentech, Inc. Serinprotease-inhibitoren
EP1059302A1 (de) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Faktor VIIa Inhibitore
US6548694B2 (en) 2000-05-23 2003-04-15 Hoffman-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
EP1332131A2 (de) 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Säurederivate und ihre verwendung als inhibitoren von serinproteasen
DE10102322A1 (de) * 2001-01-19 2002-07-25 Merck Patent Gmbh Phenylderivate
ATE438615T1 (de) 2001-04-06 2009-08-15 Biocryst Pharm Inc Biarylverbindungen als serinproteaseinhibitoren
DE10139060A1 (de) 2001-08-08 2003-02-20 Merck Patent Gmbh Phenylderivate
US6642386B2 (en) 2002-02-06 2003-11-04 Hoffmann-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
US6821974B2 (en) * 2002-03-05 2004-11-23 Barbeau Pharma, Inc Stable pharmaceutical compositions
DE10214832A1 (de) 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
US7144895B2 (en) 2003-02-11 2006-12-05 Bristol-Myers Squibb Co. Benzene acetamide compounds useful as serine protease inhibitors
EP1594505A4 (de) 2003-02-11 2008-08-13 Bristol Myers Squibb Co Phenylglycin-derivate als serin-protease-hemmer
EP1828152B1 (de) 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Heterocyclische verbindungen als inhibitoren von faktor viia
DE602006016566D1 (de) 2005-01-10 2010-10-14 Bristol Myers Squibb Co Als antikoagulanzien verwendbare phenylglycinamid-derivate
DE602006018496D1 (de) * 2005-10-05 2011-01-05 Hoffmann La Roche Naphthyridin-derivate
US7618985B2 (en) * 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives

Also Published As

Publication number Publication date
WO2007002313A3 (en) 2007-05-18
WO2007002313A2 (en) 2007-01-04
DE602006011752D1 (de) 2010-03-04
EP1910298B1 (de) 2010-01-13
EP1910298A2 (de) 2008-04-16
ES2337831T3 (es) 2010-04-29
US20070003539A1 (en) 2007-01-04
US7456195B2 (en) 2008-11-25

Similar Documents

Publication Publication Date Title
ATE455103T1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
WO2008005368A3 (en) Piperazines as p2x7 antagonists
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
DE60225671D1 (de) Pharmazeutisch wirksame piperidinderivate
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
SE0400284D0 (sv) Novel compounds
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
ATE283253T1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
MX2009006689A (es) Inhibidores viia de los factores macrociclicos utiles como anticoagulantes.
ECSP055867A (es) Derivados de pirrolopirimidina
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
ES2571779T3 (es) Inhibidores de cinasa a base de nicotinamida
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties